Description

Pregna-1,4-Diene-3,20-Dione, 6,9-Difluoro-11,21-Dihydroxy-16,17-[(1-Methylethylidene)Bis(Oxy)]-, (6β,11β,16α)- is a high-purity synthetic corticosteroid derivative, a key advanced pharmaceutical intermediate. Its value lies in its specific structural modifications, which are critical for developing potent anti-inflammatory and immunosuppressive active pharmaceutical ingredients (APIs). This compound is essential for pharmaceutical R&D and manufacturing sectors focused on next-generation topical and systemic corticosteroid therapies.

Application

• Pharmaceutical Intermediate: Primary building block for the synthesis of novel, high-potency corticosteroid APIs.
• Anti-inflammatory Drug Development: Used in research and production of medications for treating dermatological conditions like eczema, psoriasis, and dermatitis.
• Immunosuppressive Therapy: Serves as a precursor for drugs used to manage autoimmune disorders and prevent organ transplant rejection.
• Veterinary Medicine: Applied in the development of anti-inflammatory treatments for animals.
• Biochemical Research: Utilized as a reference standard and probe in steroid receptor binding studies and metabolic pathway research.
• Process Chemistry & Scale-up: Employed in optimizing synthetic routes and scaling production from laboratory to commercial batches.

Basic Information

Product Name	Pregna-1,4-Diene-3,20-Dione, 6,9-Difluoro-11,21-Dihydroxy-16,17-[(1-Methylethylidene)Bis(Oxy)]-, (6β,11β,16α)-
CAS No.	1361531-95-4
Molecular Formula	C24H30F2O6
Molecular Weight	452.49 g/mol
Synonyms	6β,9α-Difluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione; Difluoroprednisolone Acetonide Intermediate; 6,9-Difluoro-11β,21-dihydroxy-16α,17α-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 16α,17α-Isopropylidenedioxy-6α,9α-difluoroprednisolone; CAS 1361531-95-4; Fluorinated Corticosteroid Intermediate; 6,9-Difluoro Prednisolone Acetonide Derivative
EINECS	Contact for details

Quality Control

Our Pregna-1,4-Diene-3,20-Dione, 6,9-Difluoro-11,21-Dihydroxy-16,17-[(1-Methylethylidene)Bis(Oxy)]-, (6β,11β,16α)- is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets exacting pharmaceutical intermediate standards. Comprehensive Certificates of Analysis (COA) detailing purity, related substances, and residual solvents are provided to support your regulatory and production needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Loss on Drying	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.